Table 3.
Bivariate analysis of risk factors associated with 30 day mortality
| Variable | All patients, N=384, (%) | Expired at 30 days, n=70, (%) | Alive at 30 days, n=314, (%) | Odds Ratio | 95% Confidence Interval | P-value |
|---|---|---|---|---|---|---|
| Strain type* | ||||||
| Healthcare Associated | 267 (70) | 51 (19) | 216 (81) | Ref. | ||
| Community Associated | 117 (30) | 19 (16) | 98 (84) | 0.82 | 0.46-1.46 | 0.57 |
| Ethnicity | ||||||
| Caucasian | 95 (25) | 19 (20) | 76 (80) | Ref. | ||
| Hispanic | 150 (39) | 22 (15) | 128 (85) | 0.69 | 0.35-1.35 | 0.28 |
| African-American | 86 (22) | 15 (17) | 71 (83) | 0.85 | 0.40-1.79 | 0.66 |
| Other | 53 (14) | 14 (26) | 39 (74) | 1.44 | 0.65-3.17 | 0.37 |
| Gender | ||||||
| Female | 126 (33) | 34 (27) | 92 (73) | 2.28 | 1.34-3.86 | 0.003 |
| Male | 258 (67) | 36 (14) | 222 (86) | Ref. | ||
| Age | ||||||
| Mean ± SD | 51 ± 16 | 61 ± 16 | 49 ± 15 | 1.05 | 1.03-1.06 | <0.0001 |
| Median (range) | 50 (19-97) | 62 (26-97) | 48 (19-88) | |||
| Year of Infection | ||||||
| 1999 | 29 (8) | 3 (10) | 26 (90) | 0.95 | 0.21-4.28 | 0.94 |
| 2000 | 42 (11) | 12 (29) | 30 (71) | 3.28 | 1.04-10.30 | 0.04 |
| 2001 | 32 (8) | 5 (16) | 27 (84) | 1.52 | 0.39-5.75 | 0.54 |
| 2002 | 22 (6) | 3 (14) | 19 (86) | 1.30 | 0.28-5.99 | 0.74 |
| 2003 | 32 (8) | 3 (9) | 29 (91) | 0.85 | 0.19-3.83 | 0.83 |
| 2004 | 30 (8) | 8 (27) | 22 (73) | 2.90 | 0.87-10.22 | 0.08 |
| 2005 | 1 (0) | 0 (0) | 1 (100) | - | - | 0.99 |
| 2006 | 34 (9) | 5 (15) | 29 (85) | 1.41 | 0.38-5.33 | 0.61 |
| 2007 | 65 (17) | 16 (25) | 49 (75) | 2.69 | 0.90-7.94 | 0.08 |
| 2008 | 51 (13) | 10 (20) | 41 (80) | 2.00 | 0.63-6.36 | 0.24 |
| 2009 | 46 (12) | 5 (11) | 41 (89) | Ref. | ||
| Length of stay prior to culture collection | ||||||
| Mean ± SD | 20 ± 27 | 18 ± 15 | 21 ± 29 | 0.99 | 0.98-1.008 | 0.40 |
| Median (range) | 13 (3-400) | 14 (3-77) | 13 (3-400) | |||
| Type of infection | ||||||
| Skin/soft tissue | 133 (35) | 7 (5) | 126 (95) | Ref. | ||
| Blood | 74 (19) | 17 (23) | 57 (77) | 5.37 | 2.11-13.66 | 0.0004 |
| Pneumonia | 131 (34) | 40 (31) | 91 (69) | 7.91 | 3.39-18.46 | <0.0001 |
| Other** | 46 (12) | 6 (13) | 40 (87) | 2.70 | 0.86-8.50 | 0.09 |
| On appropriate anti-MRSA antibiotic at culture | 65 (17) | 15 (23) | 50 (77) | 1.44 | 0.76-2.75 | 0.29 |
| Never treated with an anti-MRSA antibiotic | 38 (10) | 11 (29) | 27 (71) | 1.98 | 0.93-4.21 | 0.08 |
| Charlson Comorbidity Score | ||||||
| Mean ± SD | 3 ± 3 | 4 ± 3 | 2 ± 3 | 1.20 | 1.09-1.31 | <0.0001 |
| Median (range) | 2 (0-12) | 3 (0-12) | 2 (0-11) | |||
| Cancer | 61 (16) | 15 (25) | 46 (75) | 1.59 | 0.83-3.05 | 0.20 |
| HIV | 9 (2) | 5 (56) | 4 (44) | 6.00 | 1.59-22.81 | 0.01 |
| Diabetes | 116 (30) | 19 (16) | 97 (84) | 0.83 | 0.46-1.49 | 0.57 |
| APACHE II Score | ||||||
| Mean ± SD | 17 ± 11 | 24 ± 9 | 16 ± 11 | 1.07 | 1.04-1.09 | <0.0001 |
| Median (range) | 17 (0-55) | 24 (0-55) | 14 (0-50) |
Ref.: reference group
*
Based on antibiotic susceptibility phenotype (MIC susceptible to gentamicin, clindamycin, and TMP-SMX)
**
Other infection type (n=46) includes 21 urinary tract infections, 19 intra-abdominal infections, 6 arterial or venous cardiovascular system infections.